Angiogenesis inhibitors: Current & future directions

Current Pharmaceutical Design

Volumn 10, Issue 1, 2004, Pages 1-9

  Mousa, Shaker A ^a   Mousa, Ahmed S ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BACTERIAL TOXIN; CARBONATE DEHYDRATASE INHIBITOR; CELL ADHESION MOLECULE; CGS 27023 A; CGS 27023A; FUNGAL PROTEIN; GROWTH FACTOR; HEPARIN; IM 862; INTERLEUKIN 12; LOW MOLECULAR WEIGHT HEPARIN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; PLACEBO; PRINOMASTAT; SEMAXANIB; SQUALAMINE; SURAMIN; TANOMASTAT; THALIDOMIDE; THROMBOCYTE FACTOR 4; TNP 40; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; ZD 0101;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER INHIBITION; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SAFETY; EXTRACELLULAR MATRIX; FIBRINOLYSIS; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEMOSTASIS; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MICROVASCULARIZATION; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK BENEFIT ANALYSIS; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0346025502     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453531     Document Type: Review

References (51)

1. Mousa SA. Mechanisms of Angiogenesis In Vascular Disorders: Potential therapeutic Targets. In Angiogenesis Inhibitors & Stimulators: Potential Therapeutic Implications. Ed. By S. Mousa, R.G. Landes, Gorgtown, TX, 2000; Chapter 1, 1-12.
2. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin system in angiogenesis. Arteriosclerosis Thrombosis Vascular Biology 2001; 21: 1104-1117.
3. Pirie-Shepherd SR. Regulation of angiogenesis by the haemostatic system. Frontiers in Bioscience 2003; 8: 286-293.
4. Pavlakovic H, Havers W, Schweigerer L. Multiple angiogenesis stimulators in a single malignancy: implications for anti-angiogenic tumor therapy. Angiogenesis 2001; 4(4): 259-262.
5. Ranieri G, Gasparini G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy. Current Drug Targets Immune Endocrinology Metabolic Disorder 2001; 1(3): 241-253.
6. Clark ER, Clark EL. Microscopic observations on the growth of blood capillaries in the living. Am J Anat 1939; 64: 251-301.
7. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000; 95: 543-550.
8. Colman RW, Pixley RA, Sainz IM, Song JS, Isordia-Salas I, Mohamed S, et al. Inhibition of angiogenesis by antibody blocking the action of proangiogenic higb-molecular-weight kininogen. J Thrombosis Haemostasis 2003; 1(1): 164-173.
9. Rickles FR, Shoji M, Abe K. The role of the haemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 2001; 73: 145-150.
10. Bromberg ME, Konigsberg WH, Madison JF. Tissue factor promotes metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205-8209.
11. Fernandez PM, Rickles FR. Tissue factor and angiogenesis in cancer. Curr Opin Haematol 2002; 9 (5): 401-406.
12. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999; 96 (15): 8663-8668.
13. Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low-density lipoprotein receptor. J Biol Chem 2001; 276:12241-12248.
14. Thompson WD, Harvey JA, Kazmi MA, Stout AJ. Fibrinolysis and angiogenesis in wound healing. J Pathol 1991; 165: 311-318.
15. Eriksson K, Magnusson P, Dixelius J, Claesson-Welsh L, Cross MJ. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 2003; 536 (1-3): 19-24.
16. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 2001; 98 (12): 6656-6661.
17. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Haemost 2002; 28(1): 45-52.
18. Mousa SA. The Low Molecular weight Heparin Tinzaparin in thrombosis and beyond. Cardiovascular Drug Review 2002; 20 (3): 163-180.
19. Wojtukiewicz M, Zacharski L, Memoli V. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990; 10: 579-82.
20. Zacharski LR, Wojtukiewicz M, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Sem Thromb Haemostasis 1992; 18: 104-16.
21. Trousseau A. Phlegmasia alba dolens. Clinique medicale do l'hoteldieu de Paris. New Sydenham Society, London 1865; 3: 94.
22. Zacharski L, Meehan K. Anticoagulants and cancer therapy. The Cancer Journal 1993; 6: 16-20.
23. Sorensen H, Mellemkjaer L, Olsen J, Baron J. Prognosis of cancers associated with venous thromboembolism. N Eng J Med 2000; 343: 1846-50.
24. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck and prostate. Cancer 1984; 53: 2046-52.
25. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994; 74: 38-45.
26. Thornes R. Coumarins, melanoma and cellular immunity. In: McBrien D, Slator T, editors. Protective agents in cancer. London: Academic Press; 1983; p. 43-56.
27. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage TV breast cancer. Lancet 1994; 343: 886-9.
28. Ferrara N. Role of vascular endothelial growth factor in physiological and pathological angiogenesis: Therapeutic Implications. Semin Oncol 2002; 29 (Suppl 16): 10-14.
29. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002; 29 (suppl 16): 3-9.
30. Chung AS, Yoon SO, Park SJ, Yuri CH. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003; 36(1): 128-137.
31. Shahan TA, Ohno N, Pasco S, Borel JP, Monboisse JC, Kefalides NA. Inhibition of tumor cell proliferation by type IV collagen requires increased levels of cAMP. Connect Tissue Res 1999; 40(3): 221-232.
32. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R. Phase Pahramacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003; 21 (2): 223-231.
33. Mousa SA Anti-integrins: Novel Therapeutic Developments Exp Opinion Invest Drugs 2001; 10 (2): 387-391.
34. Van Waes C, Enamorado I, Hecht D, Sulica L, Chen Z, Batt G, et al. Effects of the novel αv integrin antagonist SM256 and cisplatinum on growth of murine squamous cell carcinoma PAMLY8. Int. Journal of Oncology 2000; 16 (6): 1189-1195.
35. Kim S, Mousa SA, Varner J. Requirement of integrin α5β1 and its ligand fibronectin in angiogenesis. American J. Pathology 2000; 156: 1345-1362.
36. Campochiaro PA. Ocular Angiogenesis. In Angiogenesis Inhibitors & Stimulators: Potential Therapeutic Implications. Ed. By S. Mousa, R.G. Landes, Gorgtown, TX, 2000.
37. Mousa SA, Lorelli W, Campochiaro PA. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J. Cellular Biochemistry 1999; 74 (1): 135-143.
38. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA. Antagonist of Integrin avb3 Inhibit Retinal Neovascularization in Murine Model. Lab. Investigation 1996; 75 (4): 563-573.
39. Tosi P, Tura S. Antiangiogenic therapy in multiple myeloma. Acta Haematol 2001; 106(4): 208-213.
40. Bennett CL, Schumock GT, Desai AA, Kwaan HC, Raisch DW, Newlin R, et al. Thalidomide-associated deep vein-thrombosis and pulmonary embolism. Am J Med 2002; 113(7): 603-606.
41. Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20(6): 1657-1667.
42. Mousa SA. Angiogenesis, Coagulation activation, and malignant dissemination. Seminar in Thrombosis & Haemostasis 2002; 28(1): 45-52.
43. Mousa SA, Mohamed S. Anti-angiogenesis efficacy of the LMWH, tinzaparin and TFP1. Blood 1999; 94 (10): 22a, 82.
44. Jung SP, Siegrist B, Wade MR, Anthony CT, Woltering EA. Inhibition of human angiogenesis with heparin and hydrocortisone. Angiogenesis 2001; 4(3): 175-186.
45. McCarty OJT, Mousa SA, Bray P, Konstantopoulos K. Immobilized Platelet Support Human Colon Carcinoma Cell Tethering, Rolling and Firm Adhesion under Dynamic Flow Conditions. Blood 2000; 96 (5): 1789-1797.
46. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001; 20(1-2): 79-86.
47. Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothelial dysfunction in anti-angiogenesis-associated thrombosis. J Clin Oncol 2002; 20(13): 3042-3043.
48. Chen Z, Malhotra P, Thomas G, Ondrey F, Duffey D, Smith C, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clinical cancer Res 1999; (5): 1369-1379.
49. Basser R. The impact of thrombopoietin on clinical practice. Curr Pharm Design 2002; 8(5): 369-77.
50. Bilfinger TV, Stefano GB. The role of protease inhibition with emphasis on the effects of inflammation and vascular immune phenomena. Curr Pharm Design 2002; 8(7): 505-9.
51. Gordeladze JO, Reseland JE, Drevon CA. Pharmacological interference with transcriptional control of osteoblasts: a possible role for leptin and fatty acids in maintaining bone strength and body lean mass. Curr Pharm Design 2001; 7(4): 275-90.